Liquidia Q2 FY26 earnings call LQDA

YUTREPIA has demonstrated significant commercial success, accumulating approximately 5,900 unique patient prescriptions and starting over 5,000 patients on therapy within a year of launch. The product has been prescribed by more than 1,100 physicians, with 30% prescribing to five or more patients. The overall inhaled prostacyclin market grew by 6% to $607 million in Q2, with YUTREPIA's growth alone exceeding the total category expansion, indicating substantial market share capture and expansion of the overall market. YUTREPIA's net revenue is approaching 30% of the entire inhaled market.

Management emphasizes that YUTREPIA's broad adoption stems from its superior tolerability, which enables higher dosing, leading to greater efficacy and durable clinical benefit. This principle was demonstrated in the 24-week ASCENT study in PH-ILD patients, where progressively higher median doses of YUTREPIA correlated with progressive improvements in 6-minute walk distance (21.5m at week 8, 31.5m at week 16, 41m at week 24) without worsening cough scores. This highlights the critical link between tolerability, dose, and efficacy.

Building on YUTREPIA's success, Liquidia is aggressively developing L606, a twice-daily inhaled treprostinil, aiming to further enhance tolerability. The 48-week open-label study for L606 showed patients titrating across a broad dose range with a low incidence of cough, and preserved peak 6-minute walk improvements at trough. The company believes L606 is well-positioned to be successful in its Phase III Re-Spire trial, which is currently enrolling patients, and to offer incremental benefits over existing and developing treatments.

The company reported strong financial results for Q2 2026, with net product sales of YUTREPIA reaching $170.4 million, a 31% quarter-over-quarter increase. Net income rose to $74.7 million, and non-GAAP adjusted EBITDA increased to $96.3 million. Liquidia ended the quarter with $284.2 million in cash and cash equivalents, an increase of $61.4 million from Q1. This strong cash flow generation supports continued investment in the pipeline and commercialization efforts, including an expanded sales team and patient support services.

Liquidia has a thoughtful R&D plan with 10 clinical studies for YUTREPIA and L606 either underway or planned to begin over the next 12 months. This includes evaluating YUTREPIA for potential expansion into progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), with a study advancing in H1 2027. R&D expenses are projected to double in the second half of 2026 compared to the first half and increase further in 2027, reflecting the company's commitment to pipeline development.

The expanded sales force aims to deepen relationships with existing YUTREPIA prescribers and expand into the community setting, where a significant number of PH-ILD patients remain undiagnosed. Payer coverage for YUTREPIA is considered very good and at parity across the board, facilitating product choice. The company is actively educating the broader care team, including pharmacists and nurse practitioners, on YUTREPIA's benefits and ease of use, contributing to its growing market presence.

The company provided an update on the 327 trial, stating that the range of potential outcomes remains unchanged, from winning on all claims to a royalty or adjunctive relief if the ruling is unfavorable. Management has no visibility into the judge's workload but expects a decision any day now based on historical timelines for Judge Andrews. The company's confidence in the probability of success and its arguments in court remains unchanged.